Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria
Bernd Höppe(University of Bonn), Craig B. Langman(Northwestern University), David McDougall, Jaap W. Groothoff(University of Amsterdam), Kelly Barrios(Dicerna Pharmaceuticals (United States)), Graham Lipkin(Queen Elizabeth Hospital Birmingham), Gesa Schalk, Pierre Cochat(Société Nationale des Chemins de Fer Français (France)), Sander F. Garrelfs(Emma Kinderziekenhuis), Martin Coenen(University Hospital Bonn), Aniruddha Amrite(Dicerna Pharmaceuticals (United States)), Michelle A. Baum(Boston Children's Hospital), Annelize Koch
Cited by 90
Related Papers
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
|Data Archiving and Networked Services (DANS)|2003|2.5k
Fluid Overload and Mortality in Children Receiving Continuous Renal Replacement Therapy: The Prospective Pediatric Continuous Renal Replacement Therapy Registry
|American Journal of Kidney Diseases|2009|690
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4
|Nature Genetics|2006|573
Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy
|Kidney International|2005|510
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505